Rat form of the predominant Beta amyloid peptide found in plaques associated with Alzheimer’s disease. In some animal models, cognitive impairment and neurodegenerative disorders that mimic Alzheimer's disease can be reproduced by intracerebral or intracerebroventricular administration of peptide beta amyloid. Evidence suggests that oxidative stresses are involved in the mechanism of beta amyloid-induced neurotoxicity and Alzheimer’s disease pathogenesis. Exposure to beta amyloid increases lipid peroxidation, protein oxidation, and the formation of hydrogen peroxide in cultured cells. Beta amyloid peptides are also used to study oxidative stress, metal binding and mechanisms of protein cross-linking in Alzheimer’s disease and neurodegeneration.
1. Glenner, G.G. and Wong, C.W. (1984) “Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein.” Biochem. Biophys. Res. Comm. 120: 885.
2. Hong, L. et al (2010) “Quantification of the binding properties of Cu2+ to the amyloid beta peptide: coordination spheres for human and rat peptides and implication on Cu2+-induced aggregation” J. Phys. Chem. 114(34): 11261-11271.
Each peptide comes complete with the following information:
a QC summary sheet
two reverse phase HPLC profiles to verify purity
mass spectrometry to verify molecular weight
amino acid analysis to verify composition
We use outside laboratories to provide the amino acid analysis and mass spectrometry. This third-party verification allows us to remain objective and has helped us achieve an excellent record of delivering top quality peptides since 1993.